JPS59219239A - Ｂ型肝炎ウイルス表面抗原の精製方法 - Google Patents
Ｂ型肝炎ウイルス表面抗原の精製方法Info
- Publication number
- JPS59219239A JPS59219239A JP9449583A JP9449583A JPS59219239A JP S59219239 A JPS59219239 A JP S59219239A JP 9449583 A JP9449583 A JP 9449583A JP 9449583 A JP9449583 A JP 9449583A JP S59219239 A JPS59219239 A JP S59219239A
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- cellulose
- purification
- hbs antigen
- gel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 49
- 102000036639 antigens Human genes 0.000 title claims abstract description 48
- 108091007433 antigens Proteins 0.000 title claims abstract description 48
- 241000700605 Viruses Species 0.000 title claims abstract description 11
- 208000006454 hepatitis Diseases 0.000 title claims abstract description 9
- 231100000283 hepatitis Toxicity 0.000 title claims abstract description 7
- 238000000746 purification Methods 0.000 title abstract description 15
- 229920002678 cellulose Polymers 0.000 claims abstract description 32
- 239000001913 cellulose Substances 0.000 claims abstract description 32
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims abstract description 14
- 238000004440 column chromatography Methods 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims description 20
- -1 sulfate ester Chemical class 0.000 claims description 7
- 241000700721 Hepatitis B virus Species 0.000 claims description 6
- 238000004587 chromatography analysis Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 abstract description 5
- 210000002966 serum Anatomy 0.000 abstract description 5
- 238000011084 recovery Methods 0.000 abstract description 4
- 125000001174 sulfone group Chemical group 0.000 abstract description 4
- 238000010353 genetic engineering Methods 0.000 abstract description 3
- 239000011159 matrix material Substances 0.000 abstract description 3
- 238000006116 polymerization reaction Methods 0.000 abstract description 3
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 2
- 239000000047 product Substances 0.000 abstract description 2
- 230000001180 sulfating effect Effects 0.000 abstract 1
- 239000006228 supernatant Substances 0.000 abstract 1
- 239000000499 gel Substances 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 238000010828 elution Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 208000002672 hepatitis B Diseases 0.000 description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 4
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 4
- 235000011613 Pinus brutia Nutrition 0.000 description 4
- 241000018646 Pinus brutia Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 3
- 239000007979 citrate buffer Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
- 238000011067 equilibration Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 239000007975 buffered saline Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- SPSXSWRZQFPVTJ-ZQQKUFEYSA-N hepatitis b vaccine Chemical compound C([C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)OC(=O)CNC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@@H](N)CCCNC(N)=N)C1=CC=CC=C1 SPSXSWRZQFPVTJ-ZQQKUFEYSA-N 0.000 description 2
- 229940124736 hepatitis-B vaccine Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- KYARBIJYVGJZLB-UHFFFAOYSA-N 7-amino-4-hydroxy-2-naphthalenesulfonic acid Chemical compound OC1=CC(S(O)(=O)=O)=CC2=CC(N)=CC=C21 KYARBIJYVGJZLB-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229960002520 hepatitis vaccine Drugs 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- XZEUAXYWNKYKPL-URLMMPGGSA-N ormeloxifene Chemical compound C1([C@@H]2[C@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-URLMMPGGSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Inorganic materials O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9449583A JPS59219239A (ja) | 1983-05-28 | 1983-05-28 | Ｂ型肝炎ウイルス表面抗原の精製方法 |
| US06/586,702 US4515714A (en) | 1983-03-09 | 1984-03-06 | Method for purification of hepatitis B virus surface antigen |
| CA000449009A CA1216790A (en) | 1983-03-09 | 1984-03-07 | Method for purification of hepatitis b virus surface antigen |
| EP84102501A EP0118885B1 (en) | 1983-03-09 | 1984-03-08 | Method for purification of hepatitis b virus surface antigen |
| KR1019840001160A KR880002586B1 (ko) | 1983-03-09 | 1984-03-08 | B형 간염 바이러스 표면 항원의 정제방법 |
| AT84102501T ATE38152T1 (de) | 1983-03-09 | 1984-03-08 | Verfahren zur reinigung des hepatitis-b-virusoberfl|chenantigens. |
| DE8484102501T DE3474775D1 (en) | 1983-03-09 | 1984-03-08 | Method for purification of hepatitis b virus surface antigen |
| SG88/89A SG8889G (en) | 1983-03-09 | 1989-02-14 | Method for purification of hepatitis b virus surface antigen |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9449583A JPS59219239A (ja) | 1983-05-28 | 1983-05-28 | Ｂ型肝炎ウイルス表面抗原の精製方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59219239A true JPS59219239A (ja) | 1984-12-10 |
| JPH0235726B2 JPH0235726B2 (en, 2012) | 1990-08-13 |
Family
ID=14111877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9449583A Granted JPS59219239A (ja) | 1983-03-09 | 1983-05-28 | Ｂ型肝炎ウイルス表面抗原の精製方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS59219239A (en, 2012) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS52114018A (en) * | 1976-03-18 | 1977-09-24 | Kabi Ab | Purification and isolation of hepatisis virus for producing vaccine |
-
1983
- 1983-05-28 JP JP9449583A patent/JPS59219239A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS52114018A (en) * | 1976-03-18 | 1977-09-24 | Kabi Ab | Purification and isolation of hepatisis virus for producing vaccine |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0235726B2 (en, 2012) | 1990-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR880002586B1 (ko) | B형 간염 바이러스 표면 항원의 정제방법 | |
| JPS6230752B2 (en, 2012) | ||
| JPH01311028A (ja) | 肝炎蛋白質の精製 | |
| JPH0578532B2 (en, 2012) | ||
| JPH0450294B2 (en, 2012) | ||
| JPS58183629A (ja) | 非ａ非ｂ型肝炎関連モノクロナ−ル抗体および診断薬 | |
| JPH04295432A (ja) | 血液凝固ｉｘ因子を含有する複合体 | |
| JPS58201794A (ja) | ヒトインターフェロンβの濃縮精製法 | |
| JPS61145125A (ja) | 肝炎‐ｂ‐ウイルス感染性のない高純度ガンマグロブリンの調製法 | |
| JPS58159417A (ja) | 均一なヒトのインタ−フエロン及びその製造方法 | |
| JPS6078999A (ja) | ＨＢｓ抗原の精製方法 | |
| WO1981000050A1 (en) | Process for producing hepatitis b vaccine | |
| AU641119B2 (en) | Ultrapurification of factor IX and other vitamin K-dependent proteins | |
| JPS59231097A (ja) | 均質ヒト免疫インターフェロンサブタイプ２１ｋおよびその製造法 | |
| Njayou et al. | Purification of measles virus by affinity chromatography and by ultracentrifugation: a comparative study | |
| JPS59219239A (ja) | Ｂ型肝炎ウイルス表面抗原の精製方法 | |
| JPH0423751B2 (en, 2012) | ||
| JPS6154451A (ja) | 群特異性を有するアフイニテイクロマトグラフイ用ゲルおよびその製法 | |
| JPS59164727A (ja) | Ｂ型肝炎ウイルス表面抗原の精製方法 | |
| JP3476242B2 (ja) | インフルエンザｈａ蛋白の精製方法 | |
| KR0159716B1 (ko) | B형 간염 표면 항원의 정제방법 | |
| JP3158254B2 (ja) | インターフェロン精製方法 | |
| AT392417B (de) | Komplex geeignet zur durchfuehrung eines verfahrens zur reinigung von pre-s-hepatitis-b- virus-oberflaechenantigen | |
| Olson | Immunoaffinity Purification of Proteins for Injection, and the Issue of Animal Viruses | |
| JP2721961B2 (ja) | 血液製剤 |